Related Experiment Video

Updated: Mar 29, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Metabolic vulnerability of KRAS-driven cancer cells

David A Foster1

  • 1Department of Biological Sciences; Hunter College of the City University of New York; New York, NY USA.

Molecular & Cellular Oncology
|November 27, 2015
PubMed

Insights

Targeting glutamine metabolism sensitizes KRAS-driven cancers to chemotherapy by disrupting a G1 cell cycle checkpoint. This reveals new therapeutic strategies through cancer cell metabolic reprogramming.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Cell Biology

Background:

  • KRAS-driven cancers exhibit specific metabolic dependencies.
  • Glutamine anaplerosis plays a crucial role in cancer cell proliferation.
  • Chemotherapeutic agents like capecitabine and paclitaxel have limitations in efficacy.

Purpose of the Study:

  • To investigate the impact of inhibiting glutamine anaplerosis on KRAS-driven cancer cell sensitivity to chemotherapy.
  • To elucidate the underlying mechanisms by which glutamine metabolism influences chemotherapy response.
  • To identify novel therapeutic strategies targeting metabolic vulnerabilities in cancer.

Main Methods:

  • Utilizing cell culture models of KRAS-driven cancers.
  • Employing pharmacological inhibitors to interfere with glutamine anaplerosis.
  • Assessing cell viability and response to capecitabine and paclitaxel.
  • Analyzing cell cycle progression and checkpoint regulation.

Main Results:

  • Inhibition of glutamine anaplerosis sensitized KRAS-driven cancer cells to capecitabine and paclitaxel.
  • This sensitization was linked to the bypass of a glutamine-dependent G1 cell cycle checkpoint.
  • Metabolic reprogramming strategies can overcome chemotherapy resistance.

Conclusions:

  • Targeting glutamine metabolism represents a promising therapeutic strategy for KRAS-driven cancers.
  • Understanding cancer cell metabolic dependencies can uncover novel drug targets and treatment combinations.
  • Exploiting metabolic vulnerabilities offers a pathway to enhance chemotherapy efficacy.
Keywords:
GlutamineKRASTCA cycleanaplerosiscell cycle

More Related Videos

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.3K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.8K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K